Irvine Scientific Introduces New Cell Therapy Products for Cell Expansion and Differentiation

SANTA ANA, California – November 19, 2013 -- Irvine Scientific, a strategic manufacturer of cell culture media, announced today the expansion of their cell therapy product portfolio with the launch of new media and recombinant growth factors. The product line is designed to provide an integrated workflow solution for the culture of human stem cells and primary cells. In addition to the existing PRIME-XV® MSC Expansion SFM medium, intended for the expansion of human mesenchymal stem cells, Irvine Scientific is introducing three new media.  These new formulations are used for neural progenitor cell (NPC) expansion, amniotic fluid stem cell (AFSC) expansion and tumorsphere formation. To facilitate clinical applications, these media are manufactured in an ISO13485 certified facility and have pending Drug Master Files.

“A major hurdle in using stem cells and primary cells for developing therapeutic applications is the ability to generate sufficient quantities of functional cells of the targeted type,” says Dr. Jessie Ni, Chief Scientific Officer at Irvine Scientific.  “That's why our main goal when developing new products is to provide high performing media that maximizes cell growth and maintains desired cell function.”

Additionally, Irvine Scientific offers animal component-free, recombinant human growth factors such as Activin A, FGF-basic 154, and GM-CSF.

About Irvine Scientific
Irvine Scientific, a member of JX group, is a worldwide leader in the design, manufacture and distribution of medical devices, including Cell Therapy, Industrial Cell Culture, Cytogenetic, and Assisted Reproductive Technology (ART) products. Irvine Scientific is a worldwide media provider that is regulated and adheres to both ISO and FDA regulations with dual manufacturing facilities in California, USA and Tokyo, Japan. Irvine Scientific is a large scale producer of advanced quality cell culture media for the industrial bioprocess, medical, and diagnostic markets. The company’s extensive experience in the design of culture media, compliance with ISO and FDA regulations for class II / III medical devices, and industrial scale manufacturing capacity provides customers with unique capabilities and support.

Download Press Release (PDF)